The mTOR inhibitors everolimus and temsirolimus have shown significant single-agent activity in refractory/relapsed DLBCL patients, providing additional salvage therapeutic options (117, 118). The gene discussed is MTOR; the disease is diffuse large B-cell lymphoma.